MX384026B - Terapeuticos de anticuerpo que se unen a ctla4. - Google Patents
Terapeuticos de anticuerpo que se unen a ctla4.Info
- Publication number
- MX384026B MX384026B MX2017010412A MX2017010412A MX384026B MX 384026 B MX384026 B MX 384026B MX 2017010412 A MX2017010412 A MX 2017010412A MX 2017010412 A MX2017010412 A MX 2017010412A MX 384026 B MX384026 B MX 384026B
- Authority
- MX
- Mexico
- Prior art keywords
- ctla4
- antibodies
- derivatives
- polypeptides
- methods
- Prior art date
Links
- 229940124691 antibody therapeutics Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 abstract 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 abstract 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008629 immune suppression Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000027317 positive regulation of immune response Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562116353P | 2015-02-13 | 2015-02-13 | |
| PCT/US2016/017713 WO2016130898A2 (en) | 2015-02-13 | 2016-02-12 | Antibody therapeutics that bind ctla4 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017010412A MX2017010412A (es) | 2018-07-06 |
| MX384026B true MX384026B (es) | 2025-03-14 |
Family
ID=56614957
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017010412A MX384026B (es) | 2015-02-13 | 2016-02-12 | Terapeuticos de anticuerpo que se unen a ctla4. |
| MX2021007947A MX2021007947A (es) | 2015-02-13 | 2017-08-11 | Terapeuticos de anticuerpo que se unen a ctla4. |
| MX2022011935A MX2022011935A (es) | 2015-02-13 | 2017-08-11 | Terapeuticos de anticuerpo que se unen a ctla4. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021007947A MX2021007947A (es) | 2015-02-13 | 2017-08-11 | Terapeuticos de anticuerpo que se unen a ctla4. |
| MX2022011935A MX2022011935A (es) | 2015-02-13 | 2017-08-11 | Terapeuticos de anticuerpo que se unen a ctla4. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10202453B2 (OSRAM) |
| EP (3) | EP3949984A1 (OSRAM) |
| JP (3) | JP6917902B2 (OSRAM) |
| KR (1) | KR20180006367A (OSRAM) |
| CN (2) | CN108271359B (OSRAM) |
| AR (1) | AR103675A1 (OSRAM) |
| AU (2) | AU2016219170B2 (OSRAM) |
| CA (1) | CA2976446A1 (OSRAM) |
| ES (1) | ES2882157T3 (OSRAM) |
| IL (3) | IL292578A (OSRAM) |
| MX (3) | MX384026B (OSRAM) |
| TW (1) | TW201636369A (OSRAM) |
| WO (2) | WO2016130986A1 (OSRAM) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| WO2016130986A1 (en) * | 2015-02-13 | 2016-08-18 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind ctla4 |
| SI3303394T1 (sl) | 2015-05-29 | 2020-10-30 | Agenus Inc. | Protitelesa proti-CTLA-4 in postopki njihove uporabe |
| NZ739503A (en) | 2015-07-16 | 2023-06-30 | Bioxcel Therapeutics Inc | A novel approach for treatment of cancer using immunomodulation |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| WO2018035710A1 (en) * | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| JP6976322B2 (ja) * | 2016-10-10 | 2021-12-08 | クラウン バイオサイエンス，インコーポレイテッド（タイツァン） | 新規抗ｃｔｌａ４抗体 |
| IL266918B2 (en) | 2016-12-07 | 2024-03-01 | Agenus Inc | Anti-ctla-4 antibodies and methods of use thereof |
| EP3585430A4 (en) | 2017-02-21 | 2020-12-09 | REMD Biotherapeutics, Inc. | TREATMENT OF CANCER WITH ANTIBODIES THAT BIND TO T-CYTOTOXIC T-LYMPHOCYTES ANTIGEN-4 (CTLA-4) |
| CN108124445B (zh) * | 2017-03-15 | 2021-05-04 | 苏州银河生物医药有限公司 | Ctla4抗体、其药物组合物及其用途 |
| KR102372274B1 (ko) | 2017-05-19 | 2022-03-08 | 우시 바이올로직스 (상하이) 컴퍼니 리미티드 | 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체 |
| TWI799432B (zh) * | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| IL275391B2 (en) * | 2017-12-20 | 2025-05-01 | Harbour Biomed Shanghai Co Ltd | Antibodies binding ctla-4 and uses thereof |
| WO2019148444A1 (en) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| JP2021525576A (ja) * | 2018-05-31 | 2021-09-27 | ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | リンパ系を標的化した薬物送達方法 |
| US20210236547A1 (en) * | 2018-06-05 | 2021-08-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Rapid production, expansion, and increased purity of car-t cells using beads with protein l |
| CN110760002A (zh) * | 2018-07-25 | 2020-02-07 | 南京金斯瑞生物科技有限公司 | 人源化抗人ctla4单克隆抗体及其制备方法和用途 |
| IL291545B1 (en) * | 2018-10-31 | 2025-09-01 | Bioatla Llc | Anti-CTLA4 antibodies, antibody fragments, immunoconjugates thereof and uses thereof |
| CN113614109A (zh) | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | 双功能抗pd-1/il-7分子 |
| CA3123050A1 (en) | 2018-12-26 | 2020-07-02 | City Of Hope | Activatable masked anti-ctla4 binding proteins |
| CN119930820A (zh) * | 2018-12-27 | 2025-05-06 | 吉加根公司 | 抗ctla-4结合蛋白及其使用方法 |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| WO2021011480A1 (en) * | 2019-07-12 | 2021-01-21 | The Research Foundation For The State University Of New York | Compositions and methods to block and bind cxcr4 to modulate cellular function |
| WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
| EP4110810A1 (en) | 2020-02-28 | 2023-01-04 | Orega Biotech | Combination therapies based on ctla4 and il-17b inhibitors |
| MX2022015948A (es) * | 2020-07-02 | 2023-04-05 | Gigagen Inc | Proteínas de unión anti-ctla-4 y métodos de uso de estas. |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| WO2022214653A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| WO2024200823A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3817827A (en) | 1972-03-30 | 1974-06-18 | Scott Paper Co | Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
| DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6887471B1 (en) * | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| JP3589665B2 (ja) | 1992-10-23 | 2004-11-17 | イミュネックス・コーポレーション | 可溶性オリゴマー蛋白質の調製法 |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
| SI2112166T1 (sl) * | 1998-12-23 | 2019-05-31 | Pfizer Inc. | Človeška monoklonska protitelesa proti CTLA-4 |
| CN1371416B (zh) * | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
| GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
| AU2001233027A1 (en) * | 2000-01-27 | 2001-08-07 | Genetics Institute, Llc | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| MXPA02012434A (es) * | 2000-06-16 | 2004-09-06 | Cambridge Antibody Tech | Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii. |
| US6938003B2 (en) | 2000-06-30 | 2005-08-30 | Mahesh Harpale | Method and apparatus for a credibility reporting system to augment an online exchange |
| GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
| IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| BR0309254A (pt) * | 2002-04-12 | 2005-03-01 | Medarex Inc | Uso de um anticorpo anti-ctla-4 |
| MXPA05005921A (es) * | 2002-12-02 | 2005-10-19 | Abgenix Inc | Anticuerpos dirigidos a factor de necrosis tumoral y sus usos. |
| US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
| KR100845354B1 (ko) * | 2004-03-26 | 2008-07-09 | 화이자 프로덕츠 인코포레이티드 | 항－ｃｔｌａ－4 항체의 용도 |
| ES2426725T3 (es) * | 2004-05-27 | 2013-10-24 | Crucell Holland B.V. | Método para identificar moléculas de unión que pueden neutralizar el virus de la rabia |
| CN101146552A (zh) * | 2005-03-23 | 2008-03-19 | 辉瑞产品有限公司 | 用ctla4抗体和激素疗法治疗前列腺癌 |
| WO2006101692A1 (en) * | 2005-03-23 | 2006-09-28 | Pfizer Products Inc. | Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer |
| EP2240204A1 (en) * | 2008-02-04 | 2010-10-20 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
| EA023148B1 (ru) * | 2008-08-25 | 2016-04-29 | Эмплиммьюн, Инк. | Композиции на основе антагонистов pd-1 и их применение |
| EP2679681B2 (en) * | 2011-02-25 | 2023-11-15 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific FC antibody |
| GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| PT2900694T (pt) * | 2012-09-27 | 2018-11-13 | Merus Nv | Anticorpos de igg biespecíficos como ativadores de células t |
| WO2016130986A1 (en) * | 2015-02-13 | 2016-08-18 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind ctla4 |
| US20170233476A1 (en) * | 2016-02-12 | 2017-08-17 | Sorrento Therapeutics, Inc. | Antibody Therapeutics That Bind CTLA4 |
-
2016
- 2016-02-12 WO PCT/US2016/017859 patent/WO2016130986A1/en not_active Ceased
- 2016-02-12 ES ES16749944T patent/ES2882157T3/es active Active
- 2016-02-12 CN CN201680015455.8A patent/CN108271359B/zh active Active
- 2016-02-12 EP EP21183628.3A patent/EP3949984A1/en not_active Withdrawn
- 2016-02-12 WO PCT/US2016/017713 patent/WO2016130898A2/en not_active Ceased
- 2016-02-12 EP EP22189031.2A patent/EP4151231A1/en not_active Withdrawn
- 2016-02-12 EP EP16749944.1A patent/EP3256165B1/en active Active
- 2016-02-12 CN CN202111220911.1A patent/CN114014930A/zh active Pending
- 2016-02-12 MX MX2017010412A patent/MX384026B/es unknown
- 2016-02-12 KR KR1020177025857A patent/KR20180006367A/ko not_active Ceased
- 2016-02-12 IL IL292578A patent/IL292578A/en unknown
- 2016-02-12 JP JP2017560892A patent/JP6917902B2/ja active Active
- 2016-02-12 CA CA2976446A patent/CA2976446A1/en not_active Abandoned
- 2016-02-12 AR ARP160100391A patent/AR103675A1/es unknown
- 2016-02-12 US US15/043,157 patent/US10202453B2/en active Active
- 2016-02-12 AU AU2016219170A patent/AU2016219170B2/en not_active Ceased
- 2016-02-15 TW TW105104408A patent/TW201636369A/zh unknown
-
2017
- 2017-08-11 IL IL253963A patent/IL253963B/en unknown
- 2017-08-11 MX MX2021007947A patent/MX2021007947A/es unknown
- 2017-08-11 MX MX2022011935A patent/MX2022011935A/es unknown
-
2019
- 2019-01-08 US US16/243,016 patent/US11155623B2/en not_active Expired - Fee Related
-
2021
- 2021-01-05 JP JP2021000465A patent/JP2021054857A/ja not_active Withdrawn
- 2021-06-23 IL IL284336A patent/IL284336B/en unknown
- 2021-09-22 US US17/482,138 patent/US20220002415A1/en not_active Abandoned
- 2021-12-08 AU AU2021282431A patent/AU2021282431A1/en not_active Abandoned
-
2022
- 2022-04-01 JP JP2022061876A patent/JP2022084942A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX384026B (es) | Terapeuticos de anticuerpo que se unen a ctla4. | |
| MX2017010793A (es) | Terapeuticos de anticuerpo que ligan cd137. | |
| ZA202308021B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| WO2017015560A3 (en) | Antibody therapeutics that bind lag3 | |
| WO2016144803A8 (en) | Antibody therapeutics that bind tim3 | |
| WO2017152102A3 (en) | Anti-trem1 antibodies and methods of use thereof | |
| WO2017075432A3 (en) | Anti-siglec-9 antibodies and methods of use thereof | |
| PH12017500331A1 (en) | Antigen binding proteins that bind cxcr5 | |
| MY200335A (en) | Bispecific binding proteins and uses thereof | |
| WO2017062672A3 (en) | Anti-trem2 antibodies and methods of use thereof | |
| MX2022007774A (es) | Anticuerpos de union a abril modificados. | |
| HK1221964A1 (zh) | 与pd-1结合的抗原结合蛋白 | |
| WO2016164669A3 (en) | Antibody therapeutics that bind cd38 | |
| PH12014502527B1 (en) | St2 antigen binding proteins | |
| EA201790961A1 (ru) | Перенацеливающие cd3/cd38 t-клетки гетеродимерные иммуноглобулины и способы их получения | |
| MY187975A (en) | Antigen-binding proteins that activate the leptin receptor | |
| WO2013192596A3 (en) | Antigen binding proteins that bind ccr2 | |
| MX2020010094A (es) | Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos. | |
| WO2016164657A3 (en) | Antibody therapeutics that bind cd123 | |
| MA39847A (fr) | Protéines de liaison à l'antigène se liant à wisp1 | |
| PH12017500332A1 (en) | Antigen binding proteins that bind cxcr3 | |
| WO2016075546A3 (en) | Antibodies that neutralize ebola virus and uses thereof | |
| WO2018231339A3 (en) | TYROSINE PHOSPHORYLATED ANTI-PD-1 ANTIBODIES AND USES THEREOF | |
| MX2017003014A (es) | Anticuerpos anti-alfa v beta 5 humanizados y usos de estos. | |
| MX2020013243A (es) | Anticuerpos anti-il-22, fragmentos de anticuerpo, sus inmunoconjugados y usos de los mismos. |